Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) December 6, 2021
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update November 12, 2021
